Abstract
Background The significance of providing gender-affirming care has gained prominence in recent years. This study examines the hospitalization patterns of individuals with gender dysphoria, exploring the indications for hospitalization, types of gender-affirming care offered, resource utilization, and outcomes.
Methods We analyzed 67,454 discharge records from the 2016-2020 Nationwide Inpatient Sample (NIS). We identified cases of gender dysphoria using the International Classification of Diseases, 10th Revision (ICD-10) code F64.0. Demographic data, co-morbidity scores, indications for hospitalization, care patterns, length of hospital stay, mortality rates, and hospital charges were rigorously examined using ICD-10 codes and survey techniques. The trend in hospital expenditures was assessed using the Cochran-Armitage test with statistical significance set at P<.05.
Results About 53.6% were assigned female at birth, 46.4% male. The mean age was 33 ± 0.2 years. White Americans constituted 67.3%, Blacks 14.9%, Hispanics 10%, and Asians/Pacific Islanders 2.1%. Most admissions (51.6%) were ages 16-35, with 9.5% aged 60 or older. Mental health services (55.2%) and cross-sex hormonal therapy (48.8%) were common. Gender-affirming surgeries were performed in 7.1% of cases, while 0.4% received puberty-suppressing therapy. About 355 mortalities were recorded. Mortality rates increased with advancing age, with the highest mortality among individuals over 60 years old (205). No deaths occurred among those who received gender-affirming surgery. The mean length of hospital stay (LOS) was 6 days. Patients in the age range of 5 to 15 years had longer hospital stays compared to other age groups, with a mean LOS of 7.3 ± 0.2 days (P<0.001). Total hospital costs for gender-affirming care exceeded $3.3 billion, with a notable trend of increasing costs over the study period. The average costs for gender-affirming surgery, mental health services, and cross-sex hormone therapy were $101,349 ± $5,881, $41,938 ± $1,350, and $70,873 ± $13,528, respectively. Over time, mean and total costs for gender dysphoria hospitalizations increased from 400 million in 2016 to 1.3 billion in 2020 (Ptrend<0.001).
Conclusion This study reinforces the critical role of mental health services and cross-sex hormonal therapy in gender transition. It also challenges stereotypes by demonstrating that gender-affirming surgeries are sought by individuals across a wide age spectrum. However, it underscores the importance of addressing healthcare disparities, particularly for older individuals. The substantial financial costs associated with gender-affirming care underscore its significance and increasing demand. These findings emphasize the evolving healthcare needs of the gender dysphoria population, necessitating ongoing research and comprehensive support to advance gender-affirming care and understanding.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All Nationwide Inpatient Sample datasets are publicly available through the HCUP central distributor upon request at https://hcup-us.ahrq.gov/tech_assist/centdist.jsp or via direct email to the Agency for Healthcare Research and Quality at hcup@ahrq.gov
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Other emails Bojmichael1{at}gmail.com
chinwenduobijuru{at}gmail.com
shemilorahy{at}gmail.com
crystabellsonia{at}yahoo.com
sumayyahabdul435{at}gmail.com
hgyayehyirad{at}gmail.com
Ebehiremeudegbe{at}yahoo.com
Abesinolawale{at}gmail.com
orjihgeorge{at}gmail.com
Conflict of interest: The authors declare no conflicting interests